IL1B and myocardial infarction: Furthermore, SCE administration suppressed myocardial infarction (MI)-induced inflammation, as shown by the decreased levels of proinflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF), and interleukin-6 (IL-6), and the increased levels of anti-inflammatory cytokine interleukin-10 (IL-10).